On this page
Pain-care D2C startup Zanskar in talks for $6M Bessemer-led funding round
Our read
If the $6M round closes, Zanskar is likely to test whether pain care can become a defensible hybrid retail category—combining fast-delivery products with physiotherapy-led services—rather than remaining a marketplace-dependent D2C brand.
For operators
Zanskar’s prospective $6 million Bessemer-led round signals a push to deepen omnichannel pain-care distribution and test physiotherapy-led offline formats.
Watch
Formal funding announcement, final round size, valuation and participation by Bessemer or other institutional investors.
The report,
Delhi NCR pain-care D2C startup Zanskar is in talks to raise about $6 million led by Bessemer. It sells pain-relief products via its website, Blinkit, Tata 1mg, Amazon and Flipkart, and is exploring physiotherapy-led wellness-centre pilots.
Reported figures
From the report. Source details below
| ₹2.8 Cr seed round | approximately 10 months earlier |
|---|---|
| Healthtech projected to grow at 39% CAGR from | 2025 |
| Healthtech market projected to exceed $37 Bn by | 2030 |
| Healthtech deals fell to 54 in 2025 from | 78 a year earlier |
Also in the report
- 47% of Indians aged 45+ experience joint pain
- 31% suffer persistent back pain
Other figures
- Founded in 2022
Why it matters to operators
Zanskar’s planned omnichannel and clinic-pilot expansion could create partnership opportunities for pharmacies, marketplaces and healthcare operators seeking pain-care category depth.
What to watch next
- Hiring for retail operations, physiotherapy, clinical advisory, marketplace growth or city expansion.
- New offline centre launches, partnership-led clinics or franchise/managed-service structures.
- Changes in Blinkit and Tata 1mg assortment, delivery coverage, ratings, search ranking or exclusive bundles.
- Evidence of repeat-led growth: subscriptions, recovery programs, cross-category launches or reduced promotional dependence.
- Regulatory or advertising scrutiny of therapeutic, pain-relief or clinical efficacy claims.
Likely next moves
Our read of what comes next — analysis, not reported by the source.
- Secure or expand preferred placements on Blinkit, Tata 1mg, Amazon and Flipkart, especially in high-intent pain-relief searches.
- Use new capital to build clinician, physiotherapist and content-led credibility rather than relying solely on discount-driven D2C acquisition.
- Pilot small-format physiotherapy or consultation centres in Delhi NCR and one or two additional metros before committing to a broader owned-centre rollout.
- Develop bundles and subscriptions spanning topical pain relief, recovery, mobility and preventive wellness to raise repeat purchase rates.
- Pursue B2B partnerships with gyms, corporate wellness programs, orthopaedic clinics and physiotherapy networks to lower acquisition costs.
The counter-case
The case against this reading — not reported by the source.
A reported $6M round is modest relative to the cost of building an omnichannel health brand and testing service-led centres. Zanskar risks spreading capital across D2C acquisition, marketplace commissions, quick-commerce discounts, inventory and offline clinic operations before proving repeat purchase, clinical efficacy and store-level economics. Pain care is also crowded, with consumers able to switch among OTC products, physiotherapy providers, established pharma brands and marketplace alternatives.
The source
First seen